[Application of the IFN-gamma ELISPOT assay for monitoring CD8(+) T cell response to specific antigen from hepatocellular carcinoma patients].
To study the specific CD8(+) T cell response to HLA-A2 binding peptide Flu p58-66 from HLA-A2-positive hepatocellular carcinoma patients and healthy donors. The CD8(+) T cells were separated with immunobeads from PBMC of HCC patients and healthy donors, respectively. The irradiated autologous CD8(-) PBMC or isolated dendritic cells were loaded with influenza matrix peptide as APC. After 7 days' culture, the frequency of effector cells to secrete IFN-gamma in response to Flu p58-66 was detected in ELISPOT assay. With CD8(-) PBMC as APC, the frequency of effector cells to secrete IFN-gamma in response to Flu peptide was 22 +/- 9/well in HCC patients (n = 8) and 59 +/- 27/well in healthy donors (n = 12) when the effector cells were 5 x 10(4)/well (P < 0.01). To compare the antigen-presenting capacity of APC derived from 5 healthy donors, DC was better than CD8(-) PBMC. Although the frequency of specific effector CTL to secrete IFN-gamma in response to Flu p58 - 66 was lower in HCC patients than in healthy individuals, the majority of HCC patients have the cellular immunity specific to antigen peptides.